You can buy or sell EIGR and other stocks, options, ETFs, and crypto commission-free!
Eiger BioPharmaceuticals, Inc. Common Stock, also called Eiger BioPharmaceuticals, is a clinical-stage biopharmaceutical company. Read More It focuses on the development and commercialization of well-characterized drugs for life-threatening, rare and ultra-rare diseases with high unmet medical needs and no approved therapies. The company was founded by David A. Cory on November 6, 2008 and is headquartered in Palo Alto, CA.
Palo Alto, California
52 Week High
52 Week Low
PR NewswireMar 13
Eiger Late-Breaker Oral Presentation of Peginterferon Lambda Phase 2 LIMT Study at The International Liver Congress™ 2019
PALO ALTO, Calif., March 13, 2019 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced a late-breaker oral presentation of Phase 2 LIMT HDV ( L ambda I nterferon M ono T herapy in H epatitis D elta V irus) end of study 24 week post-treatment results will be presented at The International Liver Congress™ 2019 in Vienna, Austria, April 10 to 13. Peginterferon Lambda is a f...
Guru FocusMar 11
Eiger BioPharmaceuticals Management Team to Present and Participate in Jefferies HBV Investor Summit
PALO ALTO, Calif., March 11, 2019 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that David Cory, President and CEO, will present a corporate update at the Jefferies HBV Investor Summit in New York City. The HDV Investor Summit will be held on March 18th at the Jefferies Conference Center and will include company presentations, an expert panel, and one-on-one meetin...
Simply Wall StMar 8
The Eiger BioPharmaceuticals (NASDAQ:EIGR) Share Price Is Up 38% And Shareholders Are Holding On
The simplest way to invest in stocks is to buy exchange traded funds. But if you pick the right individual stocks, you could make more than that. For example, the Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) share price is up 38% in the last year, clearly besting than the market return of around -1.0% (not including dividends). If it can keep that out-performance up over the long term, investors will do very well! We’ll need to follow Eiger BioPharmaceuticals for a while to get a better sense of its share p...
-$0.82 per share
-$0.92 per share